Disclosed is a phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein the substituents are as described within the specification. Examples of compounds of formula (1) include: 4-{ [1-(4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazol-4-yl} carbonyl)morpholine and 1-(4-{ 3-[(2S)-2-methylpyrrolidin-1-yl]propoxy} phenyl)-1H-pyrazole-4-carboxamide. Further disclosed is the use of a compound of formula (1) in the manufacture of a prophylactic or therapeutic agent for dementia, Alzheimers disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression or allergic rhinitis.
